Read Online The efficacy and safety of neoadjuvant chemotherapy /- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial. - M Mohammadianpanah Affiliation: Department of Radiation Oncology, Cancer Research Center, Namazi Hospital, Shiraz University of Medical Sciences, 71936-11351 Shiraz, Iran. mohpanah@sums.ac.ir; Y Ashouri; S Hoseini; N Amadloo; A Talei; All authors | ePub
Related searches:
Efficacy and safety of neoadjuvant chemotherapy with
The efficacy and safety of neoadjuvant chemotherapy /- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Efficacy and safety of neoadjuvant chemotherapy regimens - Aging
P1. 18-06 Efficacy and Safety of Neoadjuvant PD-1 Blockade with
The safety and efficacy of neoadjuvant PD-1 inhibitor with
The efficacy and safety of neoadjuvant buparlisib for breast
Efficacy and safety of neoadjuvant PD-1 blockade with
The efficacy and safety of neoadjuvant chemotherapy on
Efficacy and Safety of Two Neoadjuvant Strategies With
Efficacy and safety of neoadjuvant trastuzumab combined with
Clinical safety and efficacy of neoadjuvant combination chem
Efficacy and safety of neoadjuvant immunotherapy in - Lung Cancer
3-year follow-up of a phase III trial comparing the efficacy and safety
Efficacy and safety of neoadjuvant pertuzumab, trastuzumab and
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab
Evaluation of Efficacy and Safety of Neoadjuvant Treatment
Efficacy and safety of neoadjuvant immunotherapy in patients
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant
Efficacy and safety of camrelizumab combined with FOLFOX as
Safety and Efficacy of Panitumumab Plus Neoadjuvant
Evaluation of the efficacy and safety of a neoadjuvant gemcitabine
ASCO 2018: A phase II Study Investigating the Safety and Efficacy of
Efficacy and safety of neoadjuvant therapy for HER2-positive
10 Original Article The safety and efficacy of neoadjuvant PD
Retrospective study of the efficacy and safety of neoadjuvant
Original Article Efficacy and safety of neoadjuvant
Efficacy and Safety of Neoadjuvant T-DM1 vs Docetaxel
Safety and Efficacy of Neoadjuvant DOF [Docetaxel
Efficacy and Safety of Azacitidine (AZA) in Combination with
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline
Retrospective study of efficacy and safety of neoadjuvant
Phase II study to evaluate the efficacy and safety of
(PDF) Efficacy and safety of neoadjuvant trastuzumab combined
Efficacy and Safety of Neoadjuvant Pembrolizumab in Patients
Efficacy and safety results from GEICO 1205, a randomized
Original Article Clinical efficacy and safety of paclitaxel
Comparison of efficacy and safety among axitinib, sunitinib, and
Efficacy and safety of dose-dense paclitaxel plus carboplatin as
Neoadjuvant therapy for patients with HER2-positive breast cancer
Safety and effectiveness of neoadjuvant luteinizing hormone
Clinical Efficacy of Including Capecitabine in Neoadjuvant - PLOS
Retrospective analysis of the efficacy and safety of
Efficacy and safety of TE/TEC/intensive paclitaxel
Original Article Efficacy and safety of capecitabine
Efficacy and safety of wait and see strategy versus radical
Efficacy and safety of nanosomal docetaxel lipid suspension
Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen
ESMO 2020 Neoadjuvant atezolizumab plus chemotherapy for
Double-blind, randomized phase III study to compare the
A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab
PERJETA® (pertuzumab) Neoadjuvant Therapy HCP
Pathological Complete Response in Neoadjuvant Treatment - FDA
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer NEJM
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab
Pembrolizumab for Early Triple-Negative Breast Cancer
A Phase 3, Randomized, Open-Label, Multicenter, Global Study
NSABP-FB12: An Open-Label Phase II Trial to Evaluate the
Expert consensus on neoadjuvant immunotherapy for non-small
Table 1 from Neoadjuvant induction dose-dense MVAC for muscle
NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in
4393 1884 710 423 1738 4362 284 1232 2616 3579 2564 1317 340 1866 4017 4508 425 1039 2766 4344 4187 1428 3236 3460 4370 78 3954 33 4070 3310 48 3063 3261 332 2768 2492 190
Aims:currently, there are many approaches available for neoadjuvant therapy for human epidermal growth factor receptor 2 (her2)-positive breast cancer that improve therapeutic efficacy but are also.
May 24, 2018 the primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed.
This is a phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (g/np) or folfirinox in the treatment of locally advanced, unresectable pancreatic cancer subjects.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial.
Interval debulking surgery (ids) after neoadjuvant chemotherapy (nac) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddtc therapy) as nac for these cancers.
Asco 2018 initial results of the abacus phase ii trial assessing atezolizumab as neoadjuvant therapy for patients with muscle-invasive bladder cancer mibc.
Objective: to assess the effectiveness and safety of neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer prior to cystectomy. Methods: this is a single-center, retrospective, cohort study at duke university hospital (duh).
However, neoadjuvant pd-1 inhibitor combined with chemotherapy has not been tested in locally advanced escc. We conducted this study to evaluate the efficacy and safety of pd-1 inhibitor in neoadjuvant chemotherapy. Methods in this study, we administered 28 adults with untreated, surgically resectable locally advanced escc.
A phase 3, randomized, open-label, multicenter, global study of efficacy and safety of neoadjuvant durvalumab in combination with gemcitabine+cisplatin followed by adjuvant durvalumab alone in muscle-invasive bladder cancer: niagara.
World journal of urology purposeto investigate the efficacy and safety of neoadjuvant induction dose-dense mvac (dd-mvac) for muscle invasive bladder cancer (mibc).
Ent study is being conducted to confirm the safety and efficacy of the additional use of tranilast with conventional preoperative adjuvant chemotherapy for patients with advanced escc. Patients and methods: between 56 and 59 patients aged between 20 and 74 years with clinically diagnosed stage ii or stage iii escc will be enrolled.
In order to determine the benefit and safety of neoadjuvant therapy, more prospective studies on the expected efficacy of neoadjuvant therapy are needed. Acknowledgments funding: the study was supported by medical health science and technology project of zhejiang provincial health commission (grant number: 2020366703).
Evaluate the efficacy and safety of neoadjuvant pembrolizumab–chemotherapy as compared with neoadjuvant placebo–chemotherapy, followed by adjuvant pembrolizumab or placebo in patients.
Sep 21, 2020 esmo 2020: nadia harbeck presents the impassion031 study of atezolizumab plus neoadjuvant chemotherapy in patients with early-stage.
Aug 22, 2017 interval debulking surgery (ids) after neoadjuvant chemotherapy (nac) is currently one of the preferred treatment options for advanced ovarian.
Aug 14, 2012 radical prostatectomy (rp) has limited cancer control potential for the patient with high-risk prostate cancer (pca).
Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis.
This study demonstrated the equivalence of efficacy between ct-p6 and reference trastuzumab in ebc patients. Secondary efficacy endpoints also supported the similarity for two study drugs. Ct-p6 was well tolerated with a similar safety profile to that of reference trastuzumab through the neoadjuvant and adjuvant period.
New life-saving treatments for non-small cell lung cancer in clinical trial on a phase iii double-blinded multicenter randomized study evaluating the efficacy and safety of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy in patients with resectable stage ii iiia or select iiib non-small cell lung cancer.
Efficacy and safety of neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer - expert commentary march 5, 2019 neoadjuvant chemotherapy followed by radical cystectomy (rc) with lymph node dissection is the standard of care in patients with muscle-invasive urothelial bladder carcinoma (mibc).
In the current study, we first evaluated the efficacy and safety of neoadjuvant sintilimab in chinese patients.
Chictr-oic-17013726 (abstract #8531; sunday, june 2, 8:00 am -11:00 am cdt), is an open-label, single-center, phase ib study in china, evaluating the efficacy and safety of neoadjuvant sintilimab.
Efficacy and safety of azacitidine (aza) in combination with the anti-pd-l1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (aml) who are unfit for intensive chemotherapy (ic) and pts with higher-risk myelodysplastic syndromes (hr-mds): results from a large, international, randomized phase 2 study.
The nadim study presented at asco in 2019 aimed to assess the safety and efficacy of preoperative neoadjuvant immunotherapy in the form of three-cycle nivolumab monotherapy plus carboplatin plus paclitaxel in patients with stage iiia (n2 or t4n0) nsclc, and results were promising.
Jan 3, 2013 thus adding capecitabine to neoadjuvant chemotherapy regimes is advanced breast cancer (labc): preliminary safety and efficacy data.
Christopher crane, md of memorial sloan-kettering gives an overview of his presentation, what is the optimal neoadjuvant strategy in pancreatic cancer,.
Jun 10, 2015 compared with alternative neoadjuvant chemotherapy regimens in combination with radiotherapy or concurrent chemoradiotherapy, the present.
Immune checkpoint inhibitors (icis) have been approved for the late-line treatment of unresectable gastrointestinal tumors, but their efficacy and safety in the neoadjuvant setting have not been described. Whether dmmr/msi-h populations benefit from preoperative icis plus surgery remains undefined.
Oct 1, 2020 efficacy and safety of neoadjuvant pertuzumab, trastuzumab and chemotherapy in non-metastatic her2-positive breast cancer in the asian.
A previously published prospective randomized phase 3 trial showed that administration of 24 weeks of primary systemic chemotherapy (pst) with paclitaxel and fec75 (fluorouraci.
Efficacy and safety of paclitaxel/docetaxel + epirubicin (te), paclitaxel/docetaxel + epirubicin + cytoxan (tec) and intensive paclitaxel (ip) neoadjuvant chemotherapy (nct) were compared for the treatment of breast cancer.
Jul 9, 2020 efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: a meta-analysis.
Evaluation of efficacy and safety of neoadjuvant treatment with pamrevlumab in combination with chemotherapy (either gemcitabine plus nab-paclitaxel or folfirinox) in locally advanced pancreatic cancer the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Gianni l, pienkowski t, im yh et al (2012) efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial.
The abacus study investigates the efficacy and safety of neoadjuvant atezolizumab given prior to cystectomy in operable urothelial mibc. This single arm, phase ii study investigated two cycles of atezolizumab (1200mg every three weeks) prior to radical cystectomy among patients with t2-4n0m0 urothelial carcinoma.
E16549 background: neoadjuvant chemotherapy for patients with locally advanced gastric and gastroesophageal junction adenocarcinoma (gc/gejc) can improve the overall survival without increasing operation risk. Nowadays, immunotherapy has become a new promising neoadjuvant treatment. Therefore, we intended to evaluate the safety and efficacy of camrelizumab (anti-pd-1 antibody) combined with.
This two-arm randomized clinical study aimed to evaluate the efficacy and safety of neoadjuvant concurrent chemotherapy and letrozole in postmenopausal women with locally advanced breast carcinoma. One hundred and one postmenopausal women aged 50-83 years with pathologically proven locally advanced.
Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for t3 or t4 stage ii/iii rectal cancer: the fact trial.
January 28, 2021 - the neoadaura trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with.
Multiple studies have evaluated the efficacy and safety of perjeta + herceptin- based neoadjuvant therapy in patients with her2+ breast cancer.
/ phase ii study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
719 - 3-year follow-up of a phase iii trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar ct-p6 in her2 positive.
Mar 23, 2021 request pdf efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic.
Efficacy and long-term safety with bevacizumab included in neoadjuvant and adjuvant therapies in patients with advanced ovarian cancer: results of the anthalya trial.
Recently, several studies have investigated the efficacy and safety of neoadjuvant buparlisib for these patients, but the results are conflicting. [24–26] this systematic review and meta-analysis of randomized controlled trials (rcts) aim to assess the efficacy and safety of neoadjuvant buparlisib versus placebo for breast cancer.
Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage ib 2-iib cervical cancer lu yang *, jianfeng guo yi shen, jing cai, zhoufang xiong, weihong dong, jie min, zehua wang.
Bct 1702 (chariot): a phase ii study evaluating efficacy and safety of ipilimumab and nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of nivolumab.
(32) aimed to investigate the safety and efficacy of preoperative neoadjuvant immunotherapy in the form of four cycles of atezolizumab monotherapy plus carboplatin plus albumin-bound paclitaxel in patients with stage ib‒iiia nsclc, and the results revealed that this treatment algorithm was feasible, tolerable, and beneficial.
Neoadjuvant pd-1 inhibitor combined with chemotherapy has not been tested in locally advanced escc. We conducted this study to evaluate the efficacy and safety of pd-1 inhibitor in neoadjuvant chemotherapy. Methods: in this study, we administered 28 adults with untreated, surgically resectable locally advanced escc.
Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with ccr response after neoadjuvant chemoradiotherapy: a meta-analysis guo-hua zhao1†, li deng2†, dong-man ye3, wen-hui wang3, yan yan3 and tao yu3* abstract.
The safety and efficacy of neoadjuvant pd-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Abstract: neoadjuvant chemotherapy (nac) contained capecitabine in breast cancer remains controversial, thus, we conducted a meta-analysis to evaluate the efficacy and safety of this regimen. Methods: we searched the pubmed, cochrane library and embase before december 2015.
Neoadjuvant chemotherapy (nact) is now used worldwide as initial therapy for treating lagc and operable gastric cancer. It has shown improvement in survival when compared to surgery alone [10] [11]. In our study we evaluated the efficacy and safety profile of patients who received neo-adjuvant chemotherapy with dof regimen.
Background studies with pertuzumab, a novel anti-her2 antibody, show improved efficacy when combined with the established her2-directed antibody trastuzumab in breast cancer therapy. We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting.
Post Your Comments: